美国 · SEC FORM 4
Prelude Therapeutics Inc
PRLD · Nasdaq · CIK 0001678660 · Healthcare · Biotechnology
内部人信号
2 位买方 · 4 条买入交易行 · $25.0M 买入总额
为什么有这个信号？
评分构成
每条进度条表示其对当前分数的贡献；权重和公式保持不变。
哪些因素限制了当前分数？
- ⚠ Cluster breadth is moderate · 2 insider(s), not 4+
- ⚠ Purchase activity is becoming less recent
- ✓ 角色得分高 · 买入者中职位最高的是：Director,TenPercentOwner
Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.
US-v1.2 按当前 180 天规则给合资格的股票买入打分。分数只表示研究的先后，不是收益预测或概率。回测没有显示美国分数越高、之后的表现越好。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
—
买方广度与集中度
Roles in the peak window: Director,TenPercentOwner. Concentration uses priced qualifying P lines only and does not change the saved score.
信号历史
最新留档分数
- 68.5
- 68.5
- 68.5
- 68.5
- 68.4
Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
市场背景补充近期价格表现与风险信息，不影响内部人信号。
价格表现
- 1M
- -16.7%
- 3M
- -12.4%
- 6M
- -4.7%
- 12M
- +173.9%
波动率与流动性
- 波动率
- 158.8%
- Beta
- —
- 平均每日成交额
- USD 1.9M
估值
- 市值
- USD 310.4M
- P/E
- —
基本面
- 利润率
- -819.6%
- ROE
- -145.0%
- 细分行业
- Biotechnology
市场数据
价格数据截至：2026-10-11 · 价格来源：OpenBB/yfinance; 成交量来自 本机价格缓存 (yfinance) · 来自 SEC 申报文件：市值, 利润率, ROE · 财年截止日：2025-12-31 · 市值 = 申报文件封面所列的已发行股数 × 最新收盘价。股数日期：2026-08-06 · Status: PASS
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 4,575,044
- 上期报告
- 3,626,569
- 日均成交量
- 578,215
- 回补天数
- 7.9
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-04-21 | ORBIMED ADVISORS LLC; ORBIMED CAPITAL LLC; OrbiMed Capital GP VI LLC; OrbiMed Genesis GP LLC | 买入 (P) | Common Stock | 2,815,315 | USD 4.44 | USD 12,499,999 | SEC 申报 ↗ |
| 2026-04-21 | Bonita David P | 买入 (P) | Common Stock | 2,815,315 | USD 4.44 | USD 12,499,999 | SEC 申报 ↗ |
| 2025-03-25 | Vaddi Krishna | 买入 (P) | Common Stock | 675,000 | USD 0.69 | USD 465,750 | SEC 申报 ↗ |
| 2025-03-25 | Combs Andrew | 买入 (P) | Common Stock | 100,000 | USD 0.69 | USD 69,000 | SEC 申报 ↗ |
| 2025-03-21 | Vaddi Krishna | 买入 (P) | Common Stock | 15,000 | USD 0.73 | USD 10,950 | SEC 申报 ↗ |
| 2025-03-20 | Vaddi Krishna | 买入 (P) | Common Stock | 5,416 | USD 0.73 | USD 3,954 | SEC 申报 ↗ |
| 2025-03-17 | Vaddi Krishna | 买入 (P) | Common Stock | 9,106 | USD 0.75 | USD 6,830 | SEC 申报 ↗ |
| 2025-03-14 | Vaddi Krishna | 买入 (P) | Common Stock | 29,999 | USD 0.75 | USD 22,499 | SEC 申报 ↗ |
| 2025-03-13 | Vaddi Krishna | 买入 (P) | Common Stock | 50,000 | USD 0.72 | USD 36,000 | SEC 申报 ↗ |
| 2025-03-12 | Vaddi Krishna | 买入 (P) | Common Stock | 47,500 | USD 0.71 | USD 33,725 | SEC 申报 ↗ |
| 2024-12-31 | Vaddi Krishna | 买入 (P) | Common Stock | 5,000 | USD 1.21 | USD 6,050 | SEC 申报 ↗ |
| 2024-12-30 | Vaddi Krishna | 买入 (P) | Common Stock | 10,000 | USD 1.20 | USD 12,000 | SEC 申报 ↗ |
| 2024-12-23 | Combs Andrew | 买入 (P) | Common Stock | 60,000 | USD 1.37 | USD 82,200 | SEC 申报 ↗ |
| 2024-12-20 | Combs Andrew | 买入 (P) | Common Stock | 3,075 | USD 1.15 | USD 3,536 | SEC 申报 ↗ |
| 2024-12-19 | Vaddi Krishna | 买入 (P) | Common Stock | 6,888 | USD 0.89 | USD 6,130 | SEC 申报 ↗ |
Form 4 申报证据
5 transaction lines in the latest 365-day window; 176 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-04-27 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Shah Rajeev M. | J (J) | Common Stock | 1,407,000 | USD — | USD — | SEC 申报 ↗ |
| 2026-04-21 | ORBIMED ADVISORS LLC; ORBIMED CAPITAL LLC; OrbiMed Capital GP VI LLC; OrbiMed Genesis GP LLC | 买入 (P) | Common Stock | 2,815,315 | USD 4.44 | USD 12,499,999 | SEC 申报 ↗ |
| 2026-04-21 | Bonita David P | 买入 (P) | Common Stock | 2,815,315 | USD 4.44 | USD 12,499,999 | SEC 申报 ↗ |
展开近期 Form 4 证据 (3 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-04-27 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Shah Rajeev M. | J (J) | Common Stock | 1,407,000 | USD — | USD — | SEC 申报 ↗ |
| 2026-04-21 | ORBIMED ADVISORS LLC; ORBIMED CAPITAL LLC; OrbiMed Capital GP VI LLC; OrbiMed Genesis GP LLC | 买入 (P) | Common Stock | 2,815,315 | USD 4.44 | USD 12,499,999 | SEC 申报 ↗ |
| 2026-04-21 | Bonita David P | 买入 (P) | Common Stock | 2,815,315 | USD 4.44 | USD 12,499,999 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | PRLD |
| CIK | 0001678660 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 176 transaction lines from 2020-09-25 to 2026-04-27 41 P purchase lines · 67 S sale lines · 68 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.